CHMP2B vs. CHMP2A Subunit Targeting Creates a Therapeutic Window in ESCRT-Dependent Tau Sorting

Target: CHMP2B, CHMP2A, CHMP4B Composite Score: 0.330 Price: $0.33 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
D
Composite: 0.330
Top 89% of 1166 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
D Mech. Plausibility 15% 0.35 Top 95%
D Evidence Strength 15% 0.32 Top 92%
B Novelty 12% 0.65 Top 69%
D Feasibility 12% 0.25 Top 94%
F Impact 12% 0.20 Top 100%
D Druggability 10% 0.30 Top 89%
F Safety Profile 8% 0.15 Top 99%
C+ Competition 6% 0.50 Top 83%
C+ Data Availability 5% 0.55 Top 61%
C Reproducibility 5% 0.40 Top 86%
Evidence
3 supporting | 4 opposing
Citation quality: 0%
Debates
1 session B+
Avg quality: 0.75
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

What is the therapeutic window between tau propagation inhibition and essential cellular function disruption?

The debate highlighted that most promising targets (VAMP2, ESCRT, fascin-1) are essential for basic cellular processes, but the specific dosing/timing parameters that could block tau transfer while preserving normal function remain undefined. This knowledge gap is critical for determining therapeutic feasibility. Source: Debate session sess_SDA-2026-04-04-gap-tau-prop-20260402003221 (Analysis: SDA-2026-04-04-gap-tau-prop-20260402003221)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (4)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing Extracellular Tau Burden
Score: 0.780 | Target: AQP4, orexin receptor (HCRTR1/2)
Conformational-Selective Blocking of Tau Uptake Reveals Therapeutic Window in Neuronal Re-entry
Score: 0.710 | Target: LRP1, HSPG (SDC3, GPC1), tau conformations
Critical Period Hypothesis: The Therapeutic Window Closes When Neuronal Homeostasis is Irreversibly Disrupted
Score: 0.640 | Target: NfL, p-tau217, p-tau231, ATF4, TOMM40
Therapeutic Window Exists Through Activity-Dependent Regulation of Synaptic Vesicle Priming
Score: 0.520 | Target: VAMP2, VAMP3, Complexin-1/2, Munc13-1

→ View full analysis & all 5 hypotheses

Description

CHMP2B is specifically involved in late endosomal sorting of ubiquitinated cargo while CHMP2A handles essential cytokinesis. Selective CHMP2B inhibition may theoretically spare essential ESCRT functions. ASSESSED AS FALSIFIED: CHMP2B knockout causes progressive neurodegeneration in vivo, directly contradicting therapeutic premise.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.35 (15%) Evidence 0.32 (15%) Novelty 0.65 (12%) Feasibility 0.25 (12%) Impact 0.20 (12%) Druggability 0.30 (10%) Safety 0.15 (8%) Competition 0.50 (6%) Data Avail. 0.55 (5%) Reproducible 0.40 (5%) 0.330 composite
7 citations 6 with PMID Validation: 0% 3 supporting / 4 opposing
For (3)
No supporting evidence
No opposing evidence
(4) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
4
MECH 3CLIN 0GENE 4EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
CHMP2B mutations cause frontotemporal dementia thr…SupportingGENE----PMID:24554770-
ESCRT-III components are recruited to tau aggregat…SupportingMECH----PMID:28800867-
Tau propagation requires functional ESCRT machiner…SupportingMECH----PMID:31982669-
CHMP2B knockout mice show progressive neurodegener…OpposingGENE----PMID:25869669-
CHMP2B mutations cause FTD through gain-of-functio…OpposingGENE----PMID:24554770-
CHMP2B loss-of-function causes disease; cannot be …OpposingGENE----PMID:25869669-
Both CHMP2A and CHMP2B participate in overlapping …OpposingMECH------
Legacy Card View — expandable citation cards

Supporting Evidence 3

CHMP2B mutations cause frontotemporal dementia through endosomal dysfunction
ESCRT-III components are recruited to tau aggregates
Tau propagation requires functional ESCRT machinery

Opposing Evidence 4

CHMP2B knockout mice show progressive neurodegeneration, not therapeutic benefit - THERAPEUTIC INDEX INVERTED
CHMP2B mutations cause FTD through gain-of-function or dominant-negative effects, not selective tau traffickin…
CHMP2B mutations cause FTD through gain-of-function or dominant-negative effects, not selective tau trafficking impairment
CHMP2B loss-of-function causes disease; cannot be therapeutically modulated without causing harm
Both CHMP2A and CHMP2B participate in overlapping ESCRT-III functions at late endosomes
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-22 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Therapeutic Hypotheses: Defining the Therapeutic Window for Tau Propagation Inhibition

Critical Knowledge Gap

The fundamental challenge: tau propagation mechanisms share molecular machinery with essential cellular processes. Defining therapeutic windows requires understanding (1) kinetic differences between pathological vs. physiological function, (2) threshold effects, and (3) spatial/temporal targeting strategies.

Hypothesis 1: Activity-Dependent Therapeutic Window via Synaptobrevin Isoform Switching

Title: "Therapeutic Window Exists Through Activity-Dependent Regula

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Therapeutic Window Hypotheses for Tau Propagation Inhibition

The debate correctly identifies that the therapeutic feasibility of these targets hinges on whether pathological and physiological functions of shared machinery can be molecularly dissociated. Below I systematically evaluate each hypothesis for evidential weaknesses, counter-evidence, falsifying experiments, and revised confidence.

Hypothesis 1: VAMP2 Isoform Switching

1. VAMP2 knockout phenotype is more severe than the hypothesis predicts. The cited PMIDs (26330554, 29127157) s

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Feasibility Assessment: Tau Propagation Inhibition Therapeutic Windows

Executive Summary

Based on the debate analysis and skeptical evaluation, I assess four hypotheses as clinically viable for further development, ranked by revised confidence and development feasibility:

| Hypothesis | Revised Confidence | Development Risk | Estimated Timeline | Key Bottleneck |
|------------|-------------------|------------------|-------------------|----------------|
| Glymphatic Enhancement | 0.75 | Low-Moderate | 6-9 years | Monotherapy efficacy |
| Extracellular Tau Conformation | 0.62

Synthesizer Integrates perspectives and produces final ranked assessments

{
"ranked_hypotheses": [
{
"title": "Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing Extracellular Tau Burden",
"description": "Enhancing glymphatic clearance reduces extracellular tau 'load' through sleep-dependent waste removal mechanisms, decreasing trans-synaptic transfer probability without directly disrupting synaptic transmission machinery. Repurposed orexin receptor antagonists (suvorexant, lemborexant) offer rapid clinical translation with established safety profiles.",
"target_gene": "AQP4, orexin receptor (HCRTR1/2)",
"di

Price History

0.320.330.34 0.35 0.31 2026-04-222026-04-222026-04-22 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (4)

Paper:24554770
No extracted figures yet
Paper:25869669
No extracted figures yet
Paper:28800867
No extracted figures yet
Paper:31982669
No extracted figures yet

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
LRP1-Dependent Tau Uptake Disruption
Score: 0.979 | neurodegeneration
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome
Score: 0.975 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 CHMP2B — PDB 6HRB Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

What is the therapeutic window between tau propagation inhibition and essential cellular function disruption?

neurodegeneration | 2026-04-06 | archived

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)